The medical device industry’s trade association, AdvaMed, has released a survey of manufacturers claiming that health reform’s 2.3-percent excise tax on the devices has forced them to move operations overseas, eliminate U.S. jobs, and cut back research and development. But we debunked these claims long ago, and the surveyed firms blame the tax for developments that stem from other factors buffeting the industry.
First, assertions that firms have moved jobs abroad because of the excise tax are simply not credible. The tax creates no incentive whatsoever to move production overseas. As we’ve explained time after time, it applies equally to imported and domestically produced devices, so it won’t make imported devices any more attractive to domestic purchasers. Also, devices produced in the United States for export are exempt from the tax, so it won’t reduce the competitiveness of U.S.-made devices in international markets.
Second, AdvaMed’s estimate of job loss doesn’t take into account offsetting changes in federal fiscal policy. If the device tax were repealed, Congress would have to offset the revenue loss by raising other taxes or cutting spending — either of which would reduce the demand for goods and services and for workers.
Third, innovation in the medical device industry has slowed in recent years for reasons unrelated to the excise tax. The tax itself will have little effect on innovation. In almost all cases, the 2.3-percent tax will not turn a profitable new device into an unprofitable one.
The medical device industry faces many challenges, including widely publicized safety concerns and product recalls, tighter federal regulations to improve product safety and effectiveness, growing pressure from larger health care providers to keep device prices down, and weak demand in developed countries. It’s easy to blame the industry’s problems on the medical device tax — but it’s not accurate.